Adamas to Present at Two Upcoming Investor Conferences
November 22 2017 - 12:42PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that
company management is scheduled to present at two upcoming investor
conferences:
- Richard A. King, the company’s Chief Operating Officer, is
scheduled to present at the 29th Annual Piper Jaffray Healthcare
Conference on Tuesday, November 28, 2017 at 10:30 a.m. ET
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and
Chief Executive Officer, is scheduled to present at the Evercore
ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday,
November 30, 2017 at 8:20 a.m. ET
In addition, the company is scheduled to host
meetings at the Global Mizuho Investor Conference on Tuesday,
December 5, 2017.
The presentations will be webcast live from the
investor relations section of the Adamas website at
http://ir.adamaspharma.com/events.cfm. Archived versions of the
webcasts will be available via replay for 30 days following the
presentations.
About Adamas Pharmaceuticals,
Inc.At Adamas, we believe in the power and promise of
medicines derived from a deep understanding of time-dependent
biology. Our expertise lies in uncovering and mapping the
relationship between disease and drug activity. From there, we
strive to create medicines with therapeutic profiles that match the
pattern of disease to drive a more significant and durable clinical
effect. This understanding of time-dependent biological processes
informs our every innovation, targeting advancement in treatment of
chronic neurologic disorders. Our portfolio includes: GOCOVRI™
(amantadine) extended release capsules (previously ADS-5102), the
first and only FDA-approved medicine for the treatment of
dyskinesia in patients with Parkinson’s disease receiving
levodopa-based therapy, with or without concomitant dopaminergic
medications; ADS-5102 in development for the treatment of multiple
sclerosis walking impairment and additional indications in
Parkinson’s disease; and ADS-4101, a high-dose, modified-release
lacosamide in development for the treatment of partial onset
seizures in patients with epilepsy. For more information, please
visit www.adamaspharma.com.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024